Review



primary antibodies against igfbp5  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech primary antibodies against igfbp5
    SiRNA and primer sequences.
    Primary Antibodies Against Igfbp5, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 37 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+igfbp5/IGFBP5+Antibody/pmc06925670-138-8-12
    Average 93 stars, based on 37 article reviews
    primary antibodies against igfbp5 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma"

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    Journal: BioMed Research International

    doi: 10.1155/2019/3210324

    SiRNA and primer sequences.
    Figure Legend Snippet: SiRNA and primer sequences.

    Techniques Used:

    Expression of IGFBP5 in KIRP patient. (a) Expression of IGFBP5 in KIRP based on sample type. IGFBP5 is down expressed in KIRP compared with normal controls ( P < 0.001). (b) Expression of IGFBP5 in KIRP based on age. The expression of IGFBP5 in each age subgroup has significance with normal group. (c) Expression of IGFBP5 in KIRP based on gender. The expression of IGFBP5 in each gender subgroup has significant with normal group, but there is no significance between male and female KIRP patients. (d) Expression of IGFBP5 in KIRP based on race. (e) Expression of IGFBP5 in KIRP based on cancer stage. (f) Expression of IGFBP5 in KIRP based on histologic subtype. KIRP = kidney renal papillary renal cell carcinoma.
    Figure Legend Snippet: Expression of IGFBP5 in KIRP patient. (a) Expression of IGFBP5 in KIRP based on sample type. IGFBP5 is down expressed in KIRP compared with normal controls ( P < 0.001). (b) Expression of IGFBP5 in KIRP based on age. The expression of IGFBP5 in each age subgroup has significance with normal group. (c) Expression of IGFBP5 in KIRP based on gender. The expression of IGFBP5 in each gender subgroup has significant with normal group, but there is no significance between male and female KIRP patients. (d) Expression of IGFBP5 in KIRP based on race. (e) Expression of IGFBP5 in KIRP based on cancer stage. (f) Expression of IGFBP5 in KIRP based on histologic subtype. KIRP = kidney renal papillary renal cell carcinoma.

    Techniques Used: Expressing

    Survival curve of IGFBP5 and its related genes. (a) Kaplan-Meier survival curve of IGFBP5 for KIRP patients. The cut off value is 36.07. (b) Kaplan-Meier survival curve of VEGFA for KIRP patients. The cut off value is 6.34. (c) Expression of IGFBP5 in KIRP based on sample type. VEGFA is down expressed in KIRP compared with normal controls ( P < 0.05) (d) Kaplan-Meier survival curve of TGF- β for KIRP patients. The cut off value is 6.34.
    Figure Legend Snippet: Survival curve of IGFBP5 and its related genes. (a) Kaplan-Meier survival curve of IGFBP5 for KIRP patients. The cut off value is 36.07. (b) Kaplan-Meier survival curve of VEGFA for KIRP patients. The cut off value is 6.34. (c) Expression of IGFBP5 in KIRP based on sample type. VEGFA is down expressed in KIRP compared with normal controls ( P < 0.05) (d) Kaplan-Meier survival curve of TGF- β for KIRP patients. The cut off value is 6.34.

    Techniques Used: Expressing

    IGFBP5 related genes with a Pearson correlation coefficient ≥0.7.
    Figure Legend Snippet: IGFBP5 related genes with a Pearson correlation coefficient ≥0.7.

    Techniques Used:

    GO and PPI analysis of IGFBP5 related genes. (a) Main GO biological processes for IGFBP5 and its related genes analyzed by Metascape analysis tools. (b) The PPI networks determined by function cluster analysis. Different color represents for different function cluster. (c) The PPI networks determined by function cluster analysis. Different color represents for different P value. GO=gene oncology. PPI = protein-protein interaction.
    Figure Legend Snippet: GO and PPI analysis of IGFBP5 related genes. (a) Main GO biological processes for IGFBP5 and its related genes analyzed by Metascape analysis tools. (b) The PPI networks determined by function cluster analysis. Different color represents for different function cluster. (c) The PPI networks determined by function cluster analysis. Different color represents for different P value. GO=gene oncology. PPI = protein-protein interaction.

    Techniques Used:

    IGFBP5 expression in human kidney tissue. (a) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by Western blotting. (b) Semiquantitative analysis of IGFBP5 expression in (a) by ImageJ. (c) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by qPCR.
    Figure Legend Snippet: IGFBP5 expression in human kidney tissue. (a) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by Western blotting. (b) Semiquantitative analysis of IGFBP5 expression in (a) by ImageJ. (c) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by qPCR.

    Techniques Used: Expressing, Western Blot

    Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).
    Figure Legend Snippet: Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).

    Techniques Used: Expressing, MTT Assay, Control, Knockdown

    Related Articles

    Western Blot:

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma
    Article Snippet: .. The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208). .. Proteins were detected with the BeyoECL Plus (Beyotime, P0018s) chemiluminescent reagent.



    Similar Products

    primary antibodies against igfbp5  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology primary antibodies against igfbp5
    Primary Antibodies Against Igfbp5, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+igfbp5/igfbp1+antibody/pm37199034-63-7-11
    Average 90 stars, based on 1 article reviews
    primary antibodies against igfbp5 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    primary antibodies against igfbp5  (Proteintech)
    93
    Proteintech primary antibodies against igfbp5
    SiRNA and primer sequences.
    Primary Antibodies Against Igfbp5, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+igfbp5/IGFBP5+Antibody/pmc06925670-138-8-12
    Average 93 stars, based on 1 article reviews
    primary antibodies against igfbp5 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    SiRNA and primer sequences.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: SiRNA and primer sequences.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques:

    Expression of IGFBP5 in KIRP patient. (a) Expression of IGFBP5 in KIRP based on sample type. IGFBP5 is down expressed in KIRP compared with normal controls ( P < 0.001). (b) Expression of IGFBP5 in KIRP based on age. The expression of IGFBP5 in each age subgroup has significance with normal group. (c) Expression of IGFBP5 in KIRP based on gender. The expression of IGFBP5 in each gender subgroup has significant with normal group, but there is no significance between male and female KIRP patients. (d) Expression of IGFBP5 in KIRP based on race. (e) Expression of IGFBP5 in KIRP based on cancer stage. (f) Expression of IGFBP5 in KIRP based on histologic subtype. KIRP = kidney renal papillary renal cell carcinoma.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: Expression of IGFBP5 in KIRP patient. (a) Expression of IGFBP5 in KIRP based on sample type. IGFBP5 is down expressed in KIRP compared with normal controls ( P < 0.001). (b) Expression of IGFBP5 in KIRP based on age. The expression of IGFBP5 in each age subgroup has significance with normal group. (c) Expression of IGFBP5 in KIRP based on gender. The expression of IGFBP5 in each gender subgroup has significant with normal group, but there is no significance between male and female KIRP patients. (d) Expression of IGFBP5 in KIRP based on race. (e) Expression of IGFBP5 in KIRP based on cancer stage. (f) Expression of IGFBP5 in KIRP based on histologic subtype. KIRP = kidney renal papillary renal cell carcinoma.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing

    Survival curve of IGFBP5 and its related genes. (a) Kaplan-Meier survival curve of IGFBP5 for KIRP patients. The cut off value is 36.07. (b) Kaplan-Meier survival curve of VEGFA for KIRP patients. The cut off value is 6.34. (c) Expression of IGFBP5 in KIRP based on sample type. VEGFA is down expressed in KIRP compared with normal controls ( P < 0.05) (d) Kaplan-Meier survival curve of TGF- β for KIRP patients. The cut off value is 6.34.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: Survival curve of IGFBP5 and its related genes. (a) Kaplan-Meier survival curve of IGFBP5 for KIRP patients. The cut off value is 36.07. (b) Kaplan-Meier survival curve of VEGFA for KIRP patients. The cut off value is 6.34. (c) Expression of IGFBP5 in KIRP based on sample type. VEGFA is down expressed in KIRP compared with normal controls ( P < 0.05) (d) Kaplan-Meier survival curve of TGF- β for KIRP patients. The cut off value is 6.34.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing

    IGFBP5 related genes with a Pearson correlation coefficient ≥0.7.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: IGFBP5 related genes with a Pearson correlation coefficient ≥0.7.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques:

    GO and PPI analysis of IGFBP5 related genes. (a) Main GO biological processes for IGFBP5 and its related genes analyzed by Metascape analysis tools. (b) The PPI networks determined by function cluster analysis. Different color represents for different function cluster. (c) The PPI networks determined by function cluster analysis. Different color represents for different P value. GO=gene oncology. PPI = protein-protein interaction.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: GO and PPI analysis of IGFBP5 related genes. (a) Main GO biological processes for IGFBP5 and its related genes analyzed by Metascape analysis tools. (b) The PPI networks determined by function cluster analysis. Different color represents for different function cluster. (c) The PPI networks determined by function cluster analysis. Different color represents for different P value. GO=gene oncology. PPI = protein-protein interaction.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques:

    IGFBP5 expression in human kidney tissue. (a) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by Western blotting. (b) Semiquantitative analysis of IGFBP5 expression in (a) by ImageJ. (c) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by qPCR.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: IGFBP5 expression in human kidney tissue. (a) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by Western blotting. (b) Semiquantitative analysis of IGFBP5 expression in (a) by ImageJ. (c) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by qPCR.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing, Western Blot

    Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing, MTT Assay, Control, Knockdown